基本信息
浏览量:1
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
个人简介
Doctor Ianthe Pitout (BSc hons, PhD) is a molecular geneticist at Murdoch University focused on RNA therapeutics to treat motor neurone disease (MND). Dr Pitout is an early career researcher with 10 years of experience in the design and evaluation of antisense oligonucleotides for translational applications.
During her PhD candidature, Dr Pitout designed an antisense oligonucleotide for modulating expression of PRPF31, the causative gene in a rare inherited retinopathy (RP11), contributing a patented molecule, VP-001 (WO2020237294A1), that has undergone preclinical development at Vision Pharma, a collaboration between PYC Therapeutics LLC and the Lions Eye Institute (Perth, Western Australia and San Diego, USA). Recently, VP-001 has received investigational new drug (IND) status by the US Food and Drug Administration to proceed to phase 1 clinical trials. Dr Pitout is also an inventor of a novel antisense oligonucleotide drug for the treatment of Optic Atrophy (WO/2022/067398). Dr Pitout has invented a novel antisense oligonucleotide, PMO-56 (patent pending) to modulate the autophagy pathway in MND.
Dr Pitout began her postdoctoral career in 2019 as an MND researcher funded by a consumer group, The Racing for MNDi Foundation (Western Australia), to design antisense therapeutics for both inherited and sporadic MND.
She was also Group Leader of CNS discovery at a PYC Therapeutics, where she managed a drug discovery team of 8 research scientists (3 postdoctoral researchers and 5 research assistants) and designed novel antisense oligonucleotide drug candidates. During this time, she also held an academic position at Murdoch University and is a co- supervisor to a PhD candidate and two honours students, both undertaking research projects in MND. She has been principal or co-investigator on several grants to progress her academic research interests to understand the pathogenesis of neurodegenerative disease and was recently CIB on a successful WA Innovation Seed grant application to part-fund the preclinical progression of PMO-56, for which she is the primary inventor.
Dr Pitout's research is supported and funded by a local consumer group, the Racing for MNDi Foundation https://www.racingformndi.com.au/research/
研究兴趣
论文共 281 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCESno. 6 (2024): 3391
CLINICAL AND EXPERIMENTAL OPHTHALMOLOGYno. 9 (2023): 917-918
引用0浏览0引用
0
0
Nucleic acid therapeuticsno. 3 (2023): 178-192
Jarichad Toosaranont, Sukanya Ruschadaariyachat,Jantarika Kumar Arora,Varodom Charoensawan,Bhoom Suktitipat, Thomas N. Palmer,Sue Fletcher,Steve D. Wilton,Chalermchai Mitrpant,Warasinee Mujchariyakul
加载更多
作者统计
#Papers: 270
#Citation: 6436
H-Index: 33
G-Index: 72
Sociability: 6
Diversity: 0
Activity: 1
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn